Hypomethylating Agents in Combination With Histone Deacetylase Inhibitors in Higher Risk Myelodysplastic Syndromes: Is There a Light at the End of the Tunnel?

Cancer - United States
doi 10.1002/cncr.30532
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Is There Light at the End of the Tunnel?

Anesthesia and Analgesia
AnesthesiologyPain Medicine
1985English

Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Six (Or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2006English

Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes

Seminars in Oncology
OncologyHematology
2011English

Transplantation for Myelodysplastic Syndrome in the Era of Hypomethylating Agents

Current Opinion in Hematology
Hematology
2012English

Tracheal Transplantation: Is There Lumen at the End of the Tunnel?

Sao Paulo Medical Journal
Medicine
2009English

Plasma Exchange for Acute on Chronic Liver Failure: Is There a Light at the End of the Tunnel?

Hepatology International
Hepatology
2016English

Chronic Total Occlusions--A Stiff Challenge Requiring a Major Breakthrough: Is There Light at the End of the Tunnel?

Heart
Cardiovascular MedicineCardiology
2005English

The Unified Patent Court: Pros and Cons of Specialization – Is There a Light at the End of the Tunnel (Vision)?

IIC International Review of Intellectual Property and Competition Law
LawInternational RelationsPolitical Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy